Clinical trials: Lesion of Brain
Parkinson Disease
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers
- Trial name
- NCT03733561
- Testing
- LY03003, Neupro 4Mg/24Hr Transdermal Patch
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Atrial Fibrillation
Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)
The purpose of the study is to determine the rate of diffusion weighted (DW)-MRI cerebral lesions following a Pulmonary Vein Ablation Catheter (PVAC) ablation procedure performed using best practices, including optimized…
- Trial name
- ERACE (NCT01520532)
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- 7 sites in Belgium, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Central Nervous System Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.
- Trial name
- NCT00395460
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Magnevist
- Where
- 4 sites in China
- Volunteers
- 147 people
- Sponsor
- Bayer
Alzheimer's Disease
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal…
- Trial name
- NCT01399125
- Testing
- Rivastigmine Patch, Rivastigmine Capsules
- Where
- 16 sites in China
- Volunteers
- 501 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
MRI-based Artificial Intelligence Software (NNS-SOT) for Onset Time Estimation in Lesion With Acute Ischemic Stroke
This study evaluates the efficacy of investigational device named Stroke Onset Time Artificial Intelligence(AI) (Model name:NNS-SOT).
- Trial name
- NCT06160726
- Where
- South Korea
- Volunteers
- 474 people
- Sponsor
- Nunaps Inc
Central Nervous System Infections, Pseudotumor Cerebri
A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control
This study will compare the VerTouch device to the conventional palpation technique for performing diagnostic and therapeutic neuraxial procedures.
- Conditions
- Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer
- Trial name
- NCT04796935
- Testing
- Tactile Imaging (VerTouch), Control (palpation)
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- IntuiTap Medical, Inc
Alzheimer's Disease
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
This study evaluated the safety and efficacy of 10 cm^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm^2 for at…
- Trial name
- ADEPT (NCT00561392)
- Testing
- Rivastigmine 5 and 10 cm^2 patch
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Novartis
Alzheimer's Disease
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study was to investigate the 5cm^2 and 10cm^2 doses of rivastigmine transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's Disease (MMSE [Mini Mental State Examination] 10-20).
- Trial name
- NCT00423085
- Testing
- Rivastigmine transdermal patch
- Where
- Japan
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24).
- Trial name
- NCT00428389
- Testing
- Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
- Where
- 23 sites in United States
- Volunteers
- 262 people
- Sponsor
- Novartis
Acute Ischemic Stroke Patients
Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.
The clinical trial is for acute ischemic stroke patients measuring cerebral oxygen saturation (rSO2) values using pulse oximeter of near-infrared spectroscopy in the frontal lesion area and normal area of brain.
- Trial name
- fNIRS (NCT06250608)
- Testing
- Pulse oximeter, NIRSITX
- Where
- 2 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- OBELAB, Inc.
Multiple Sclerosis
Scan-Rescan Sub-Study of MS PATHS
The primary objective of this sub-study is to calculate the reproducibility and other technical performance measures of various magnetic resonance imaging (MRI) image analysis algorithms in order to assess their suitability for…
- Trial name
- NCT04123353
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Biogen
Brain Tumor
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system.
- Trial name
- NCT00147056
- Testing
- ExAblate transcranial system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- InSightec
Symptomatic Aortic Stenosis
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
The Keystone Heart TriGuard™ HDH is an aortic embolism deflection device intended to reduce the amount of embolic material that may enter the carotid, subclavian, and vertebral arteries during transcatheter heart valve…
- Trial name
- NCT02536196
- Testing
- Embolic Protection Device, Transcatheter aortic valve implantation (TAVI)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 478 people
- Sponsor
- Keystone Heart
Carotid Artery Stenosis
Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)
Clinical Trial Summary Trial Title:** CREATE Trial: Safety and Efficacy of IVL for Carotid Calcified Lesions Sponsor:** Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
- Trial name
- CREATE (NCT06936176)
- Testing
- Neurovascular Intravascular Shockwave Catheter
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
The purpose of this study is to evaluate the efficacy and safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI); to explore the effective dose of HRS-9231 for CNS MRI; and to explore the population…
- Trial name
- NCT06731829
- Testing
- HRS-9231, Gadobutrol
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Dementia, Parkinson Disease
Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera
This study evaluates SPECT image data acquired from Spectrum Dynamics' multi-purpose CZT SPECT-CT camera. All subjects will undergo routine clinical Anger SPECT imaging and an additional SPECT acquisition on the CZT SPECT camera.
- Conditions
- Dementia, Parkinson Disease, Pulmonary Hypertension, Heart Diseases
- Trial name
- NCT03438123
- Testing
- CZT SPECT imaging
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Spectrum Dynamics
Alzheimer Disease
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of…
- Trial name
- NCT00506415
- Testing
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2
- Where
- 145 sites in United States, Canada and 5 more
- Volunteers
- 1,584 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.